1
LETTER FROM THE CEO
During the fiscal year ended March 31, 2000, the healthcare arena continued to
be a very challenging field. The oxygen conserver market has matured and evolved
into a commodity market affected largely by features and pricing. Competition
remains fierce, the federal government continues to look at ways to reduce
healthcare spending, and it appears there will be ongoing pressure from all of
these forces.
The Company has been working hard to overcome these challenges and supply our
customers, primarily the homecare providers, with products they can utilize to
increase revenues and provide a better quality of care for their patients at
less cost. This is the objective for the TOTAL O2(R) Delivery System, which was
introduced in 1998. I will discuss below our strategy for improving and
increasing usage of this product through customer education, cost reduction
efforts and in-house manufacturing and engineering improvements. This is also
the objective of the development projects we have underway that are designed to
improve and expand our oxygen conserver line, as explained below.
The current market conditions have created a difficult environment in which to
expand the usage of the TOTAL O2 system. The market penetration for this product
increased during the year, however, the rate of increase remains slow. While we
are able to show homecare providers that the TOTAL O2 system is the most
cost-effective method of providing home oxygen, its higher relative acquisition
cost continues to be an obstacle. This is not unlike the reaction CHAD received
in the early years, after the introduction of the OXYMATIC(R) conserver. We
continue to educate homecare providers regarding the benefits of the TOTAL_O2
system. These benefits include the higher quality of service it provides to home
oxygen patients who now can control their own supply of portable oxygen without
being dependent on deliveries from the provider, as well as the lower monthly
servicing cost the homecare provider can achieve while using this system.
We will also continue our efforts to reduce the cost of the TOTAL O2 system and
thus minimize an obstacle to faster market penetration. Toward this end, we have
recently brought several manufacturing processes in-house that previously were
done by outside vendors. This is an ongoing process and will have the effect of
lowering our manufacturing costs over time. We were able to do this by
converting some offices to manufacturing space at our Chatsworth facility as
part of our continuing effort to minimize operating costs.
Through our combined strategy of educating and increasing homecare providers'
awareness of the TOTAL O2 system's benefits, reducing the cost of the system and
continuously improving the system based on feedback from our customers, we
believe that the TOTAL O2 system will ultimately be a successful product.
Additionally, we have recently obtained CE mark approval for the TOTAL O2
system. This will allow shipment of this product throughout Europe and to a
number of other international markets. We expect to capitalize on this approval
during the fiscal year ending March 31, 2001. To aid in this effort, we recently
added an Asia/Pacific manufacturer's representative in Hong Kong to support
distributors throughout this international region. In the course of the year,
we also added eight new international distributors, significantly increasing the
international sales potential for both the TOTAL O2 system and the OXYMATIC
conserver products.
We also made progress in upgrading our oxygen conserver line of products. This
effort is directed toward stemming the erosion of sales of our core product, the
OXYMATIC 301 conserver, which continued to lose market share throughout most of
the year. This occurred in spite of reduced pricing and increased selling
efforts by our field sales organization of independent manufacturer's
representatives. The first of these new products, the OXYMATIC 401 conserver,
offers a number of improvements relative to its predecessor, the OXYMATIC 301
conserver, which is now five years old. These improvements include a by-pass
switch for continuous flow in the event of an emergency, expanded flow rates to
six liters per minute and an integrated brass regulator. The 510(k) clearance
from the FDA was received in June, 2000. This product was first shown at the
Medtrade West Exhibit in Las Vegas, Nevada on May 4 and 5, 2000, and was very
well received. We expect this new product offering to allow CHAD to regain some
of the market share that has been lost over the
3
2
LETTER FROM THE CEO
past several years. In addition, we have several other projects underway that
are at various stages of development. These projects are designed to provide an
array of products in the conserver field to satisfy the homecare providers'
needs and potentially further expand market share. These projects were generated
by both licensed and internally developed technologies.
As part of our effort to expand our product line and improve the time frame in
which we can bring new products to market, we made some organizational changes
during the year. Mr. Oscar J. Sanchez, one of CHAD's original seven employees,
has taken on the role of Vice President of Business Development. With Oscar's
strong engineering background and many industry contacts developed over the
years, he will be responsible for identifying new product opportunities, as well
as assisting me with the international sales efforts.
In addition, we promoted Mr. Kevin McCulloh to Vice President, Engineering.
Kevin came to CHAD in July of 1998 from Litton Life Support where he had sixteen
years of broad-based experience in product design and development. In his time
with us, Kevin has exhibited strong organizational skills with the projects he
has managed. With Kevin's leadership, we will continue our effort to strengthen
our engineering capabilities in the upcoming year.
While we did not achieve our goal of returning to profitability during the year
ended March 31, 2000, primarily due to the continued erosion in sales of the
OXYMATIC 301 conserver, we did improve our cash position. Through diligent
inventory management and control of operating expenses, we increased our cash
balance from $137,000 at March 31, 1999, to $1,772,000 at March 31, 2000. We
still have no long-term debt and have sufficient resources to achieve our
operating goals for the upcoming year.
As we enter the new fiscal year, we have high expectations on several fronts.
First, as previously mentioned, we are optimistic about the market potential for
the OXYMATIC 401 conserver, which was recently introduced to the home oxygen
market. We also currently plan to introduce at least one or two additional
products during the fiscal year ending March 31, 2001. Each of these new
products is designed to enhance the revenue generating potential of CHAD. We
expect, at long last, to take advantage of the international sales potential of
the TOTAL O2 system. We also expect to make further progress in the cost
reduction efforts on the TOTAL O2 product. This, along with the reduced pricing
that cost reduction will allow, should aid in the rate of market penetration for
this key product.
While we cannot predict the future with any certainty, the result of achieving
these goals would be increased volume, with opportunities for continued growth
and a greater likelihood for returning to profitability for CHAD during the
upcoming fiscal year. There are still challenges to overcome before we get to
that end; however, we will exert our best efforts to achieve these goals.
Thomas E. Jones
/s/ THOMAS E. JONES
- -------------------------------
Chief Executive Officer
4
3
SELECTED FINANCIAL DATA
SELECTED FINANCIAL DATA YEARS ENDED MARCH 31,
--------------------------------------------------------------------------------------
2000 1999 1998 1997 1996
------------ ------------ ------------ ---------- ----------
Net Sales $ 12,774,000 $ 14,064,000 $ 16,593,000 26,161,000 20,359,000
Interest Income 43,000 41,000 164,000 113,000 97,000
Net Earnings (loss) (2,511,000) (1,464,000) 797,000 5,035,000 4,310,000
Basic Earnings (loss) Per Share (.25) (.15) .08 .51 .44
Diluted Earnings (loss) Per Share (.25) (.15) .08 .49 .42
Net Working Capital 8,389,000 10,164,000 10,704,000 10,985,000 9,219,000
Total Assets 13,583,000 15,899,000 17,436,000 15,861,000 10,778,000
Shareholders' Equity 12,207,000 14,693,000 16,074,000 15,110,000 9,775,000
No cash dividends have been declared or paid during the periods presented.
5
4
BALANCE SHEETS
MARCH 31,
------------ ------------
ASSETS 2000 1999
------------ ------------
Current assets:
Cash $ 1,772,000 137,000
Accounts receivable, less allowance for doubtful
accounts of $95,000 and $88,000 in 2000 and 1999,
respectively 2,003,000 2,165,000
Inventories (Note 2) 5,297,000 7,642,000
Income taxes refundable (Note 3) 175,000 687,000
Prepaid expenses 518,000 294,000
Deferred income taxes (Note 3) -- 445,000
------------ ------------
Total current assets 9,765,000 11,370,000
------------ ------------
Property and equipment, at cost:
Office equipment and furniture 1,597,000 1,688,000
Machinery and equipment 840,000 830,000
Tooling 1,098,000 1,066,000
Leasehold improvements 1,797,000 1,782,000
------------ ------------
5,332,000 5,366,000
Less accumulated depreciation and amortization 2,731,000 2,086,000
------------ ------------
Net property and equipment 2,601,000 3,280,000
------------ ------------
Other assets, net (Note 4) 1,217,000 1,249,000
------------ ------------
$ 13,583,000 15,899,000
============ ============
LIABILITIES AND SHAREHOLDERS' EQUITY 2000 1999
------------ ------------
Current liabilities:
Accounts payable $ 314,000 227,000
Accrued expenses (Note 7) 1,062,000 979,000
------------ ------------
Total current liabilities 1,376,000 1,206,000
------------ ------------
Commitments (Note 8)
Shareholders' equity (Note 5):
Common shares, no par value
Authorized 40,000,000 shares;
10,035,000 and 10,012,000 shares issued
and outstanding 13,077,000 13,052,000
Retained earnings (Accumulated deficit) (870,000) 1,641,000
------------ ------------
Net shareholders' equity 12,207,000 14,693,000
------------ ------------
$ 13,583,000 15,899,000
============ ============
See accompanying notes to financial statements.
6
5
STATEMENTS OF OPERATIONS
YEARS ENDED MARCH 31,
--------------------------------------------------
2000 1999 1998
------------ ------------ ----------
Net sales $ 12,774,000 14,064,000 16,593,000
Cost of sales 8,995,000 9,768,000 8,670,000
------------ ------------ ----------
Gross profit 3,779,000 4,296,000 7,923,000
Costs and expenses:
Selling, general and administrative 5,451,000 6,119,000 6,042,000
Research and development 560,000 625,000 713,000
------------ ------------ ----------
Total costs and expenses 6,010,000 6,744,000 6,755,000
------------ ------------ ----------
Operating income (loss) (2,231,000) (2,448,000) 1,168,000
Interest income, net 43,000 41,000 164,000
------------ ------------ ----------
Earnings (loss) before income taxes (2,188,000) (2,407,000) 1,332,000
Income tax expense (benefit) (Note 3) 323,000 (943,000) 535,000
------------ ------------ ----------
Net earnings (loss) $ (2,511,000) (1,464,000) 797,000
============ ============ ==========
Basic earnings (loss) per share $ (.25) (.15) .08
============ ============ ==========
Diluted earnings (loss) per share $ (.25) (.15) .08
============ ============ ==========
Weighted shares outstanding:
Basic 10,024,000 10,012,000 9,958,000
Diluted 10,024,000 10,012,000 10,214,000
============ ============ ==========
See accompanying notes to financial statements.
7
6
STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED MARCH 31, 2000 , 1999 AND 1998
COMMON SHARES (NOTE 5)
--------------------------- RETAINED TREASURY
SHARES AMOUNT EARNINGS SHARES
---------- ----------- ----------- -----------
Balance at March 31, 1997 9,951,000 $12,834,000 $ 2,308,000 $ (32,000)
Common shares repurchased at cost -- -- -- (285,000)
Common shares issued for purchases
under employee benefit plan -- -- -- 186,000
Exercise of stock options 57,000 156,000 -- --
Tax benefit from exercise of
non-qualified stock options -- 103,000 -- --
Stock option grants -- 7,000 -- --
Net earnings -- -- 797,000 --
---------- ----------- ----------- -----------
Balance at March 31, 1998 10,008,000 13,100,000 3,105,000 (131,000)
Common shares repurchased at cost -- -- -- (104,000)
Common shares issued for purchases
under employee benefit plan -- (72,000) -- 235,000
Exercise of stock options 4,000 24,000 -- --
Net loss -- -- (1,464,000) --
---------- ----------- ----------- -----------
Balance at March 31, 1999 10,012,000 13,052,000 1,641,000 --
Common shares issued in lieu of
cash for directors fees 23,000 25,000 -- --
Net loss -- -- (2,511,000) --
---------- ----------- ----------- -----------
Balance at March 31, 2000 10,035,000 $13,077,000 $ (870,000) $ --
========== =========== ============ ===========
See accompanying notes to financial statements.
8
7
STATEMENTS OF CASH FLOWS
YEARS ENDED MARCH 31,
------------------------------------------------
2000 1999 1998
----------- ----------- -----------
Cash flows from operating activities:
Net earnings (loss) $(2,511,000) (1,464,000) 797,000
Adjustments to reconcile net earnings (loss) to net cash provided by (used
in) operating activities:
Depreciation and amortization 894,000 894,000 617,000
Loss on disposition of property and equipment -- 77,000 --
Compensation expense related
to option grants and stock issued 25,000 -- 7,000
Changes in assets and liabilities:
Decrease (increase) in accounts receivable 162,000 304,000 (140,000)
Decrease (increase) in inventories 2,345,000 (509,000) (1,070,000)
Decrease (increase) in income taxes refundable 512,000 (115,000) (45,000)
Decrease (increase) in prepaid expenses (224,000) (45,000) (77,000)
Decrease (increase) in deferred income taxes 445,000 (381,000) 292,000
Decrease (increase) in other assets (60,000) 64,000 (431,000)
Increase (decrease) in accounts payable 87,000 (503,000) 386,000
Increase (decrease) in accrued expenses 83,000 347,000 225,000
Increase (decrease) in income taxes payable -- -- 103,000
----------- ----------- -----------
Net cash provided by (used in) operating activities 1,758,000 (1,331,000) 664,000
----------- ----------- -----------
Cash flows (used in) investing activities:
Capital expenditures (123,000) (194,000) (1,431,000)
----------- ----------- -----------
Cash flows from financing activities:
Exercise of stock options -- 24,000 156,000
Common shares purchased -- (104,000) (285,000)
Common shares issued -- 163,000 186,000
----------- ----------- -----------
Net cash provided by financing activities -- 83,000 57,000
----------- ----------- -----------
Net increase (decrease) in cash 1,635,000 (1,442,000) (710,000)
Cash beginning of year 137,000 1,579,000 2,289,000
----------- ----------- -----------
Cash end of year $ 1,772,000 137,000 1,579,000
=========== =========== ===========
Supplemental disclosure of cash flow information:
Cash paid during the year for:
Income taxes $ -- -- 185,000
=========== =========== ===========
Supplemental schedule of noncash investing and financing activities:
Tax benefit from exercise of non-qualified stock options $ -- 103,000
=========== =========== ===========
See accompanying notes to financial statements.
9
8
NOTES TO FINANCIAL STATEMENTS
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
THE COMPANY
Chad Therapeutics, Inc. (the Company) is in the business of developing,
producing and marketing respiratory care devices designed to improve the
efficiency of oxygen delivery systems for home health care and hospital
treatment of patients suffering from pulmonary diseases.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts of financial instruments approximate fair value as of March
31, 2000 and 1999. The carrying amounts related to cash, accounts receivable,
other current assets, accounts payable and accrued expenses approximate fair
value due to the relatively short maturity of such instruments.
INVENTORIES
Inventories are valued at lower of cost or market. Cost is determined based on
standard cost which approximates the first-in, first-out method.
DEPRECIATION
Depreciation of property and equipment is provided using the straight-line
method based on the estimated useful lives of the related assets as follows:
Office Equipment and Furniture 5-10 Years
Machinery and Equipment 5-10 Years
Tooling 4 Years
Amortization of leasehold improvements is over the life of the related lease or
asset, whichever is shorter.
USE OF ESTIMATES
Management of the Company has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the disclosure of
contingent assets and liabilities at the balance sheet date and the reporting of
revenues and expenses during the periods to prepare these financial statements
in conformity with generally accepted accounting principles. Actual results
could differ from those estimates.
The Company amortizes its intangible assets using the straight line method over
the remaining estimated economic life of the asset. The Company continually
evaluates the carrying value of intangible assets. Considerable management
judgement is necessary to estimate future operating cash flows as future cash
flows are impacted by competitive and other factors that are generally out of
management's control. Accordingly, actual results could vary significantly from
management's estimates. Any impairment would be recognized when the expected
future operating cash flows derived from such intangible assets is less than
their carrying value.
IMPAIRMENT OF LONG-LIVED ASSETS
The Company reviews its long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of an asset may not
be recoverable. Recoverability of assets to be held and used is measured by a
comparison of the carrying amount of an asset to undiscounted future net cash
flows expected to be generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured by the amount by which the
carrying amount of the assets exceeds the fair market value of the assets.
REVENUE RECOGNITION
Revenue from product sales is recognized upon shipment of merchandise. Reserves
for customer returns have not been established as historical experience has been
minor.
COMPREHENSIVE INCOME
Comprehensive income is the change in equity of a business enterprise during a
period from transactions and all other events and circumstances from
non-shareholder sources. Other comprehensive income includes foreign currency
items, minimum pension liability adjustments and unrealized gains and losses on
certain investments in debt and equity securities. The Company did not have
components of other comprehensive income during the periods ended March 31,
2000, 1999 and 1998. As a result, comprehensive income (loss) is the same as net
earnings (loss) for the periods ended March 31, 2000, 1999 and 1998.
EARNINGS PER COMMON SHARE
The Company accounts for net earnings per common share in accordance with the
Statement of Financial Accounting Standards No. 128. Following is a calculation
of basic and diluted earnings (loss) per common share for the years ended March
31, 2000, 1999 and 1998, respectively:
2000 1999 1998
------------ ------------ ------------
Basic earnings per share
Numerator - net earnings (loss) $ (2,511,000) (1,464,000) 797,000
Denominator - common
shares outstanding 10,024,000 10,012,000 9,958,000
------------ ------------ ------------
Basic earnings per share $ (.25) $ (.15) $ .08
============ ============ ============
Diluted earnings (loss) per share
Numerator - net earnings (loss) $ (2,511,000) (1,464,000) 797,000
Denominator -
Common shares outstanding 10,024,000 10,012,000 9,958,000
Common stock options -- -- 256,000
------------ ------------ ------------
10,024,000 10,012,000 10,214,000
------------ ------------ ------------
Diluted earnings (loss) per share $ (.25) $ (.15) $ .08
============ ============ ============
Options to purchase 979,000 and 1,045,000 shares of common stock at prices
ranging from $.88 to $12.54 and from $1.50 to $12.54 per share were not included
in the computation of diluted earnings per share in 2000 and 1999 because their
inclusion would be anti-dilutive.
INCOME TAXES
Income taxes are accounted for under the asset and liability method. Deferred
tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates expected to apply to
taxable income in the years in which those temporary differences are expected to
be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date.
10
9
NOTES TO FINANCIAL STATEMENTS
MAJOR CUSTOMER
The Company had sales to one major customer which accounted for approximately
11% of net sales during the year ended March 31, 1998. No one customer exceeded
10% of net sales during 2000 and 1999. The Company's customers are affected by
Medicare reimbursement policy as approximately 80% of home oxygen patients are
covered by Medicare and other government programs.
STOCK OPTION PLAN
The Company accounts for its stock option plan in accordance with the provisions
of Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to
Employees, and related interpretations. The Company has also adopted the pro
forma disclosure provisions of Statement of Financial Accounting Standards
(SFAS) No. 123, Accounting for Stock-Based Compensation, which permits entities
to provide pro forma net income and pro forma earnings per share disclosures for
employee stock option grants made in 1995 and subsequent years as if the
fair-value-based method defined in SFAS No. 123 had been applied.
SEGMENT INFORMATION
The Financial Accounting Standards Board issued Statement No. 131, "Disclosures
about Segments of an Enterprise and Related Information" ("FAS 131"), in June
1997. FAS 131 establishes standards for the way public business enterprises are
to report information about operating segments in annual financial statements
and requires enterprises to report selected information about operating segments
in interim financial reports issued to shareholders. It also establishes
standards for related disclosures about products and services, geographic areas
and major customers. It replaces the "industry segment" concept of FAS No. 14,
"Financial Reporting for Segments of a Business Enterprise", with a "management
approach" concept as to the basis for identifying reportable segments. FAS 131
is effective for financial statements for periods beginning after December 15,
1997. The Company adopted FAS 131 in the annual financial statements of the
fiscal year ending March 31, 1999. The Company operates in only one segment, the
respiratory care market.
(2) INVENTORIES
At March 31, 2000 and 1999, inventories consisted of the following:
2000 1999
---------- ---------
Finished goods $1,783,000 1,619,000
Work in process 654,000 1,278,000
Raw materials
and supplies 2,860,000 4,745,000
---------- ---------
$5,297,000 7,642,000
========== =========
During the years ended March 31, 2000 and 1999, the Company incurred inventory
write-downs totaling $294,000 and $734,000.
(3) INCOME TAXES
The provision (benefit) for income taxes for fiscal 2000, 1999 and 1998 consists
of the following:
2000 1999 1998
--------- -------- -------
Current:
Federal $(123,000) (517,000) 137,000
State 1,000 (45,000) 106,000
--------- -------- -------
(122,000) (562,000) 243,000
Deferred:
Federal 231,000 (183,000) 274,000
State 214,000 (198,000) 18,000
--------- -------- -------
445,000 (381,000) 292,000
--------- -------- -------
Total $ 323,000 (943,000) 535,000
========= ======== =======
A reconciliation of the difference between the Company's provision (benefit) for
income taxes and the statutory income tax for the years ended March 31, 2000,
1999 and 1998, respectively, is as follows:
2000 1999 1998
----------- ----------- -----------
Statutory tax
expense (benefit) $ (744,000) (819,000) 453,000
State income tax, net (91,000) (109,000) 82,000
Valuation Allowance 1,151,000 -- --
Warranty and other 10,000 -- --
Tax Credits, Net (3,000) (15,000) --
----------- ----------- -----------
$ 323,000 (943,000) 535,000
=========== =========== ===========
The tax effects of temporary differences that give rise to significant portions
of the deferred tax assets at March 31, 2000 and 1999 are presented as follows:
2000 1999
----------- -----------
Bad debt reserves $ 41,000 38,000
Accrued expenses 324,000 193,000
Inventories 357,000 258,000
Net Operating Loss 517,000 79,000
Tax Credits 55,000 44,000
----------- -----------
Total deferred tax assets 1,294,000 612,000
Deferred tax liabilities:
Depreciation (27,000) (97,000)
State Taxes (116,000) (70,000)
----------- -----------
Subtotal 1,151,000 445,000
Valuation Allowance (1,151,000) --
----------- -----------
Net deferred tax assets $ -- 445,000
=========== ===========
In assessing the realizability of deferred tax assets, management considers
whether it is more likely than not that some portion or all of the deferred tax
assets will be realized. At March 31, 2000, the Company's net deferred tax
assets are fully offset by a valuation allowance. The Company will continue to
assess the valuation allowance and to the extent it is determined that such
allowance is no longer required, the tax benefit of the remaining net deferred
tax assets will be recognized in the future.
(4) OTHER ASSETS
Other assets includes $1,250,000 paid in 1997 and 1998 for a license on a new
product and $150,000 paid in 2000 on new and existing products. The license fee
is being amortized
11
10
NOTES TO FINANCIAL STATEMENTS
beginning in 1998 using the straight-line method over the life of the related
patents, 14 years. Accumulated amortization on the license fee amounted to
$212,000 and $121,000 at March 31, 2000 and 1999, respectively.
(5) SHAREHOLDERS' EQUITY
In 1999 and 1998 the Company purchased its own stock for purposes of funding
contributions to the Company's 401(k) plan. Periodically as common shares were
sold to the plan, the difference between the cost and fair market value at the
date of transfer was charged or credited to shareholders' equity.
The Company has an incentive stock option plan (the Plan) for key employees as
defined under Section 422(A) of the Internal Revenue Code. The Plan as amended,
provides that 1,509,000 common shares be reserved for issuance under the Plan,
which expires on September 10, 2004. In addition, the Plan provides that
non-qualified options can be granted to directors and independent contractors of
the Company. Transactions involving the stock option plan are summarized as
follows:
WEIGHTED
AVERAGE
OPTION OPTION PRICE
SHARES AMOUNT PER SHARE
----------- ----------- ---------
Incentive Options:
Outstanding --
March 31, 1997 566,000 $ 3,698,000 6.53
Cancelled (30,000) (372,000) 12.40
Granted 254,000 2,492,000 9.81
Exercised (2,000) (10,000) 5.98
----------- ----------- -----
Outstanding --
March 31, 1998 788,000 5,808,000 7.37
Cancelled (30,000) (225,000) 7.39
Expired (226,000) (2,221,000) 9.88
Granted 349,000 1,532,000 4.38
Exercised (1,000) (8,000) 5.08
----------- ----------- -----
Outstanding --
March 31, 1999 880,000 4,886,000 5.55
Cancelled (261,000) (1,510,000) 5.79
Granted 204,000 216,000 1.06
----------- ----------- -----
Outstanding --
March 31, 2000 823,000 $ 3,592,000 4.36
=========== =========== =====
Exercisable --
March 31, 2000 458,000 $ 2,281,000 4.98
=========== =========== =====
Non-qualified Options:
Outstanding --
March 31, 1997 182,000 $ 1,267,000 6.96
Granted 26,000 267,000 10.27
Exercised (55,000) (146,000) 2.66
----------- ----------- -----
Outstanding --
March 31, 1998 153,000 1,388,000 9.07
Granted 15,000 118,000 7.63
Exercised (3,000) (16,000) 5.18
----------- ----------- -----
Outstanding --
March 31, 1999 165,000 1,490,000 9.03
Cancelled (25,000) (96,000) 3.84
Granted 16,000 35,000 2.19
----------- ----------- -----
Outstanding --
March 31, 2000 156,000 $ 1,429,000 9.16
=========== =========== =====
Exercisable --
March 31, 2000 130,000 $ 1,323,000 10.18
=========== =========== =====
At March 31, 2000, information regarding outstanding options is summarized as
follows:
RANGE OF EXERCISE PRICES
$1.50-6.69 7.63-12.54
---------- ----------
Number outstanding 731,000 248,000
Weighted average
remaining life (yrs.) 6.5 6.4
Weighted average
exercise price $ 3.25 10.42
Number exercisable 422,000 165,000
Weighted average
exercise price $ 4.28 10.85
Incentive and non-qualified options were granted at prices not less than 100% of
fair market value at dates of grant. Options under the Plan become exercisable
on the anniversary of the grant date on a prorata basis over a defined period
and expire 10 years after the date of grant. To the extent the Company derives a
tax benefit from options exercised by employees, such benefit is credited to
Common Stock when realized on the Company's income tax returns.
The Company applies Accounting Principles Board Opinion No. 25 in accounting for
the Plan and no compensation expense has been recognized for its stock options
in the accompanying financial statements. Had compensation cost for awards under
the Company's stock option plan been determined based upon the fair value at the
grant date prescribed under Statement of Financial Accounting Standards No. 123,
the Company's net earnings (loss) in 2000, 1999 and 1998 would have been reduced
(increased) by approximately ($266,000), ($415,000) and $247,000, respectively,
and earnings (loss) per share would have been reduced (increased) by ($.03),
($.04) and $.02 per share in 2000, 1999 and 1998, respectively. The weighted
average fair value of options granted during 2000, 1999 and 1998 is estimated at
$.75, $2.03 and $5.41, respectively. The disclosure of compensation cost under
this pronouncement may not be representative of the effects on net earnings
(loss) for future years. The fair value of options granted during each period
was estimated using the Black-Scholes option pricing model with the following
assumptions:
2000 1999 1998
---- ---- ----
Risk-free interest rate 5.9% 5.9% 5.9%
Forfeiture rate 2.0% 2.0% 2.0%
Dividend yield .0 .0 .0
Volatility 82% 63% 57%
Expected life (years) 5.0 5.0 5.0
(6) EMPLOYEE BENEFIT PLAN
In December, 1992, the Company adopted a defined contribution profit sharing
plan, including features under Section 401(k) of the Internal Revenue Code. The
purpose of the plan is to provide an incentive for employees to make regular
savings for their retirement. Company contributions to the profit sharing plan
are discretionary and are determined by the Board of Directors. The Company has
accrued and paid $59,000 of plan contributions during 1998. There were no
contributions in 2000 and 1999.
12
11
NOTES TO FINANCIAL STATEMENTS
(7) ACCRUED EXPENSES
Accrued expenses consist of the following:
2000 1999
---------- ----------
Accrued royalties $ 262,000 126,000
Product and business
liability insurance 48,000 63,000
Deferred rent 57,000 74,000
Accrued vacation 97,000 80,000
Retirement liability 208,000 271,000
Other 390,000 365,000
---------- ----------
$1,062,000 979,000
========== ==========
At March 31, 2000, the Company had an obligation to pay its founder and former
Chief Executive Officer $75,000 per year in retirement pay for three years. The
retirement liability represents the net present value of this obligation.
(8) COMMITMENTS
The Company is currently leasing its administrative and plant facilities and
certain office equipment under noncancelable operating leases which expire
through June, 2003.
The Company's minimum annual rental commitments under these leases are as
follows:
2001 $ 344,000
2002 354,000
2003 368,000
2004 93,000
----------
TOTAL: $1,159,000
==========
Rent expense amounted to $430,000, $442,000 and $440,000 for the years ended
March 31, 2000, 1999 and 1998, respectively.
The Company is involved in certain legal actions resulting from the ordinary
course of business. The Company believes the ultimate outcome of the legal
actions will not have a material adverse impact on the Company's financial
position.
(9) GEOGRAPHIC INFORMATION
The Company has one reportable operating segment as defined in Note 1.
Geographic information regarding the Company's sales is as follows:
2000 1999 1998
----------- ---------- ----------
United States $11,508,000 12,350,000 14,866,000
Germany 40,000 642,000 632,000
All other countries 1,226,000 1,072,000 1,095,000
----------- ---------- ----------
$12,774,000 14,064,000 16,593,000
=========== ========== ==========
All long-lived assets are located in the United States.
Sales of OXYMATIC(R) conservers and OXYLITE(R) systems accounted for 56%, 72%
and 82% of the Company's sales for the years ended March 31, 2000, 1999 and
1998, respectively.
(10) VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
The following is the Company's schedule of activity in the valuation and
qualifying accounts and reserves for the years ended March 31, 2000, 1999 and
1998:
BALANCE AT CHARGED TO BALANCE
BEGINNING COSTS AND AT END
OF YEAR EXPENSES DEDUCTIONS OF YEAR
---------- ---------- ---------- -------
ALLOWANCE FOR
DOUBTFUL ACCOUNTS:
1998 $107,000 37,000 39,000 105,000
1999 105,000 117,000 134,000 88,000
2000 88,000 59,000 52,000 95,000
(11) QUARTERLY FINANCIAL DATA (UNAUDITED)
The following table presents summarized unaudited quarterly financial data for
2000 and 1999:
BASIC
NET EARNINGS
GROSS EARNINGS (LOSS)
REVENUE PROFIT (LOSS) PER SHARE
----------- ----------- ----------- ---------
2000
- ----
First Quarter $ 3,638,000 $ 1,321,000 $ (154,000) $ (0.02)
Second Quarter 3,416,000 1,108,000 (434,000) (0.04)
Third Quarter 2,959,000 915,000 (683,000) (0.07)
Fourth Quarter 2,761,000 435,000 (1,240,000) (0.12)
----------- ----------- ----------- --------
Year $12,774,000 $ 3,779,000 $(2,511,000) $ (0.25)
=========== =========== =========== ========
1999
- ----
First Quarter $ 4,197,000 $ 1,940,000 $107,000 $ .01
Second Quarter 3,860,000 1,514,000 2,000 .00
Third Quarter 2,983,000 377,000 (894,000) (.09)
Fourth Quarter 3,024,000 465,000 (679,000) (.07)
----------- ----------- ----------- --------
Year $14,064,000 $ 4,296,000 $(1,464,000) $ (.15)
=========== =========== =========== ========
In the fourth quarters of 2000 and 1999, the Company recorded an inventory
write-down of $294,000 and $298,000, respectively.
(12) NEW ACCOUNTING PRONOUNCEMENTS
In March, 2000 the Financial Accounting Standards Board (FASB) issued FASB
Interpretation No. 44 (Interpretation 44), Accounting for Certain Transactions
Involving Stock Compensation. Interpretation 44 provides criteria for the
recognition of compensation expense in certain stock-based compensation
arrangements that are accounted for under Accounting Principles Board Opinion
No. 25, Accounting for Stock-Based Compensation. Interpretation 44 is effective
July 1, 2000, with certain provisions that are effective retroactively to
December 15, 1998 and January 12, 2000. Interpretation 44 is not expected to
have an impact on the Company's financial statements.
13
12
INDEPENDENT AUDITORS REPORT
THE BOARD OF DIRECTORS AND SHAREHOLDERS
Chad Therapeutics, Inc.
We have audited the accompanying balance sheets of Chad Therapeutics, Inc. as of
March 31, 2000 and 1999 and the related statements of operations, shareholders'
equity and cash flows for each of the years in the three year period ended March
31, 2000. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Chad Therapeutics, Inc. as of
March 31, 2000 and 1999 and the results of its operations and its cash flows for
each of the years in the three year period ended March 31, 2000, in conformity
with generally accepted accounting principles.
/s/ KMPG LLP
Los Angeles, California
May 5, 2000
14
13
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
The Company develops, assembles and markets medical devices that furnish
supplementary oxygen to home health care patients. The Company was a pioneer in
developing oxygen conserving devices that enhance the quality of life for
patients by increasing their mobility and, at the same time, lower operating
costs by achieving significant savings in the amount of oxygen actually required
to properly oxygenate patients. The market for oxygen conserving devices has
been significantly affected during the past several years by increased
competition, consolidation among home oxygen dealers and revisions (and proposed
revisions) in governmental reimbursement policies. All of these factors, as
described more fully below, have contributed to an erosion of the company's
market share, as devices that are less expensive but which provide lower oxygen
savings (or, in some cases, do not truly provide ambulatory oxygen) have
prospered in this environment. The Company's market share for conservers has
also been affected by the introduction of competing devices that offer features
not available on the OXYMATIC 301.
The TOTAL O2 Delivery System, which combines the benefits of an oxygen
concentrator with a system enabling patients to refill their portable cylinders,
has the potential for significantly improving the Company's performance.
Introduced in 1998, the acceptance of the TOTAL O2 system by home oxygen dealers
has been slowed by several factors discussed below. As a result, the increased
sales generated by the TOTAL O2 system has, to date, failed to make up for lower
OXYMATIC 301 sales.
In order to address this situation, the Company has implemented a four-part
strategy:
- - Development of the OXYMATIC 401 model with improved features, which
should place this oxygen conserver at the forefront of the industry;
- - Development of additional oxygen conserver models that will diversify
the product line in order to offer customers a range of oxygen
conservation choices;
- - A continued promotional and educational campaign with respect to the
benefits of the TOTAL O2 system, coupled with greater focus on
monitoring the performance of component suppliers; and
- - Cost cutting to align the Company's operating expenses more closely
with its revenue profile.
While the Company believes that these measures should enhance its competitive
position and future operating performance, no assurances can be given that these
objectives will be achieved. Management of the Company will continually monitor
the success of these efforts and will attempt to remain flexible in order to
adjust to possible future changes in the market for oxygen conserving devices.
RESULTS OF OPERATIONS
Sales for the years ended March 31, 2000 and 1999, decreased $1,290,000 (9.2%)
and $2,529,000 (15.3%), respectively, from the prior years. While there have
been price reductions in 2000 and 1999, the decrease in sales relates primarily
to decreases in domestic unit sales of OXYMATIC conservers and OXYLITE complete
portable oxygen systems, which are being affected by the current marketing
environment for home oxygen therapy discussed below.
Sales to foreign distributors represented 10%, 12% and 10% of total sales for
the years ended March 31, 2000, 1999 and 1998, respectively. Currently,
management expects an increase in sales to foreign distributors during the
upcoming fiscal year, however, quarter-to-quarter sales may fluctuate depending
on the timing of shipments. In addition, all foreign sales are denominated in
U.S. dollars, thus, annual unit sales could be affected by foreign currency
fluctuations.
The current procedure for reimbursement by Medicare for home oxygen services
provides for a prospective flat-fee monthly payment based solely on the
patient's prescribed oxygen requirement. Under this system, inexpensive
concentrators have grown in popularity because of their low cost and less
frequent servicing requirements. At the same time, interest heightened in oxygen
conserving devices, such as the Company's products, which can extend the life of
oxygen supplies and reduce the number of service calls by dealers, thereby
providing improved mobility for the patient and operating cost savings for
dealers. In January of 1998 and 1999, the Federal government implemented
reimbursement cuts of 25% and 5%, respectively. These cuts affected homecare
providers' purchasing patterns as they struggled to deal with significant
reductions in their revenues.
In addition, other changes in the health care delivery system, including the
increase in the acceptance and utilization of managed care, have stimulated a
significant consolidation among home oxygen providers. As major national and
regional home medical equipment chains attempt to secure managed care contracts
and improve their market position, they have expanded their distribution
networks through the acquisition of independent dealers in strategic areas.
Three major national chains accounted for approximately 20%, 21% and 24% of the
Company's domestic sales for the years ended March 31, 2000, 1999 and 1998,
respectively. Margins on these sales are generally lower due to quantity
pricing. In some instances consolidation has resulted in reduced purchases as
the former independent provider complies with the chain's purchasing policies.
To ensure continued awareness of the benefits of the Company's products by chain
headquarters' personnel, a proactive marketing and communication program is in
effect with all of the major national chains.
15
14
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
As stated above, the Company believes that its revenues during the past two
years have been adversely affected by several factors, including pricing and
competitive products with features not presently found in the Company's
products, continuing industry consolidation and the effects of the cuts in
Medicare home oxygen reimbursement on homecare providers' purchasing patterns.
The effects of managed care and concerns over the severity of reimbursement cuts
has, in many cases, resulted in the provision of systems to patients that do not
provide truly ambulatory oxygen. Management believes these factors may continue
to adversely affect the Company's revenues from sales of oxygen conserving
devices for the foreseeable future. To combat the erosion in sales of the oxygen
conserver product line, the Company is working on the development of several new
products in this area. The first of these, the OXYMATIC 401 conserver, received
510(k) clearance from the Food and Drug Administration in June, 2000. Management
believes the features and improvements in this product will allow the Company to
regain some of the market share lost in the conserver market over the past three
years. No estimate can currently be made regarding the level of success the
Company may achieve with the OXYMATIC 401 conserver. For information which may
affect the forward looking statements made in this paragraph about the OXYMATIC
401 conserver, see Outlook: Issues and Risks - New Product.
Management also believes, based on its experience in the home oxygen industry,
future revenues may be positively affected by sales of the TOTAL O2 Delivery
System. The TOTAL O2 system provides stationary oxygen for patients at home,
portable oxygen, including an oxygen conserving device, for ambulation, and a
safe and efficient mechanism for filling portable oxygen cylinders. This should
provide homecare dealers with means to deal with the reimbursement cuts
discussed above by reducing their monthly cost of servicing patients while at
the same time providing a higher quality of service by maximizing ambulatory
capability. The Company received clearance in November 1997, to sell this
product from the Food and Drug Administration. The Company began shipping TOTAL
O2 systems in January 1998, and realized approximately $2,666,000 and $1,446,000
in sales during the years ended March 31, 2000 and 1999, respectively. Initial
sales of the TOTAL O2 system have been adversely affected by several factors,
including the overall home oxygen market climate, as well as start-up
manufacturing and related supplier quality issues. The Company has taken a
number of steps to resolve the manufacturing and supplier issues. The Company
believes the sales potential for the new system is significant as the market
size for units is similar to the conserver market and the average selling price
is approximately four times that of the OXYMATIC and OXYLITE systems. No
estimate can currently be made regarding the level of success the Company may
achieve with the TOTAL O2 system. For information that may affect the forward
looking statements made in this paragraph about the TOTAL O2 system, see
Outlook: Issues and Risks - New Product.
Cost of sales as a percent of net sales increased from 69.4% to 70.4% and from
52.3% to 69.4% for the years ended March 31, 2000 and 1999, respectively. Both
periods have been affected by decreased sales volume and the corresponding
impact of fixed overhead costs on units produced, price competition and the
lower gross profit margin on the TOTAL O2 system. The year ended March 31, 1999,
was also affected by costs associated with the replacement of two suppliers of
components for the TOTAL O2 system and inventory write-downs totaling $513,000,
of which $77,000 was charged to General and Administrative expenses.
Selling, general and administrative expenditures decreased from $6,119,000 to
$5,451,000 and increased from $6,042,000 to $6,119,000 for the years ended March
31, 2000 and 1999, respectively. The Company anticipates that recent cost
reduction efforts, including reductions in personnel, should align staffing and
operating expenses more closely with current sales expectations, but will be
offset to some extent by commissions to be paid to the Company's new field sales
force of manufacturer's representatives. This field sales force has recently
been hired and trained, and now provides full coverage in the United States.
Historically, the Company has relied entirely on its internal sales personnel
and extensive marketing efforts to generate sales. The shift to a field sales
force will cause selling, general and administrative expenses to fluctuate more
closely with sales volume. Research and development expenses decreased by
$65,000 and $88,000 for the years ended March 31, 2000 and 1999, respectively,
as compared to the prior years. Currently, management expects research and
development expenditures to total approximately $700,000 in the fiscal year
ended March 31, 2001, on projects to enhance and expand the Company's product
line. Interest income increased $2,000 for the year ended March 31, 2000, as
compared to the prior year due to the increase in the Company's cash balances in
2000.
At March 31, 2000, the Company had fully utilized its net operating loss
carrybacks and had approximately $1,100,000 and $1,600,000 in Federal and
California net operating loss carryforwards, respectively. As a result of
valuation reserves placed on the net operating loss carryforwards and deferred
tax assets, the Company had a net income tax expense of $323,000 for the year
ended March 31, 2000. These net operating loss carryforwards and deferred tax
assets will be available to offset future income tax expense.
FINANCIAL CONDITION
At March 31, 2000, the Company had cash totaling $1,772,000 or 13% of total
assets, as compared to $137,000 (1%) at March 31, 1999. Net working capital
decreased from $10,164,000 at March 31, 1999 to $8,389,000 at March 31, 2000.
Accounts receivable decreased $162,000 during the year ended March 31, 2000, due
to the decline in sales. Future increases or decreases in accounts receivable
will generally coincide with sales volume fluctuations and the timing of
shipments to foreign customers. During the same period, inventories decreased
$2,345,000. This decrease relates primarily to utilization of raw materials
purchased in the prior year for the manufacture of the new TOTAL O2 product
line. The Company attempts to maintain sufficient inventories to meet
16
15
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
its customer needs as orders are received. Thus, future inventory and related
accounts payable levels will be impacted by the ability of the Company to
maintain its safety stock levels. If safety stock levels drop below target
amounts, then inventories in subsequent periods will increase more rapidly as
inventory balances are replenished. Currently, inventory balances are generally
at or above safety stock levels.
Management believes funds derived from operations should be adequate to meet the
Company's cash requirements for the next twelve months. The Company expects
capital expenditures during the next twelve months to be approximately $150,000.
The Company has not adopted any programs that provide for post employment
retirement benefits, however, it has on occasion provided such benefits to
individual employees.
YEAR 2000
All of the Company's systems performed properly on January 1, 2000, and the
Company does not anticipate any year 2000 compliance problems.
OUTLOOK: ISSUES & RISKS
This annual report contains forward-looking statements that reflect the
Company's current views with respect to future events and financial performance.
These forward-looking statements are subject to certain risks and uncertainties
that may cause actual operating results to differ materially from currently
anticipated results. Among the factors that could cause actual results to differ
materially are the following:
DEPENDENCE UPON A SINGLE PRODUCT LINE
Although the Company currently markets a number of products, these products
comprise a single product line for patients requiring supplementary oxygen.
Thus, the Company's future performance is thus dependent upon developments
affecting this segment of the health care market and the Company's ability to
remain competitive within this market sector.
NEW PRODUCTS
The Company's future growth in the near term will depend in significant part
upon the commercial success of the TOTAL O2 Delivery System, the OXYMATIC 401
conserver and other new products that are under development. The success of
these new products will depend upon the health care community's perception of
the system's capabilities, clinical efficacy and benefit to patients, obtaining
timely regulatory approval, as well as timely resolution of manufacturing and
supplier issues for the TOTAL O2 system. In addition, prospective sales will be
impacted by the degree of acceptance achieved among home oxygen dealers and
patients requiring supplementary oxygen. As with the introduction of any new
product, the Company's ability to successfully promote the TOTAL O2 Delivery
System, the OXYMATIC 401 conserver and other new products cannot be assessed at
this time.
CONSOLIDATION OF HOME CARE INDUSTRY
The home health care industry is undergoing significant consolidation. As a
result, the market for the Company's products is increasingly influenced by
major national chains. Three major national chains accounted for 20% of the
Company's domestic sales during the year ended March 31, 2000. Future sales may
be increasingly dependent on a limited number of customers that may have an
impact on margins due to quantity pricing.
COMPETITION
CHAD's success in the early 1990s has drawn new competition to vie for a share
of the home oxygen market. These new competitors include both small and very
large companies. While the Company believes the quality of its products and its
established reputation will continue to be a competitive advantage, some
competitors have successfully introduced lower-priced products with features not
currently found in the Company's products, but which do not provide oxygen
conserving capabilities comparable to the Company's products. No assurance can
be given that increased competition in the home oxygen market will not continue
to have an adverse affect on the Company's operations.
RAPID TECHNOLOGICAL CHANGE
The health care industry is characterized by rapid technological change. The
Company's products may become obsolete as a result of new developments. The
Company's ability to remain competitive will depend to a large extent upon its
ability to anticipate and stay abreast of new technological developments related
to oxygen therapy. The Company has limited internal research and development
capabilities. Historically, the Company has contracted with outside parties to
develop new products. Some of the Company's competitors have substantially
greater funds and facilities to pursue research and development of new products
and technologies for oxygen therapy.
POTENTIAL CHANGES IN ADMINISTRATION OF HEALTH CARE
A number of bills proposing to regulate, control or alter the method of
financing health care costs have been discussed and certain of such bills have
been introduced in Congress and various state legislatures. There are wide
variations among these bills and proposals. Because of the uncertain state of
the health care proposals, it is not meaningful at this time to predict the
effect on the Company if any of these proposals is enacted.
Approximately 80% of home oxygen patients are covered by Medicare and other
government programs. Federal law has altered
17
16
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
the payment rates available to providers of Medicare services in various ways
during the last several years. Congress has passed legislation that has reduced
Medicare spending. It cannot yet be predicted how future changes in
reimbursement levels will affect the home oxygen industry and there can be no
assurance that such changes will not have an adverse effect on the Company's
business.
PATENTS AND TRADEMARKS
The Company pursues a policy of obtaining patents for appropriate inventions
related to products marketed or manufactured by the Company. The Company
considers the patentability of its products to be significant to the success of
the Company. To the extent that the products to be marketed by the Company do
not receive patent protection, competitors may be able to manufacture and market
substantially similar products. Such competition could have an adverse impact
upon the Company's business.
PRODUCTS LIABILITY
The nature of the Company's business subjects it to potential legal actions
asserting that the Company is liable for damages for product liability claims.
Although the Company maintains products liability insurance in an amount that it
believes to be customary in the industry, there is no assurance that this
insurance will be sufficient to cover the costs of defense or judgments that
might be entered against the Company. The type and frequency of these claims
could have an adverse impact on the Company's results of operations and
financial position.
AVAILABILITY OF THIRD PARTY COMPONENT PRODUCTS
The Company tests and packages its products in its own facility. Some of its
other manufacturing processes are conducted by other firms and the Company
expects to continue using outside firms for certain manufacturing processes for
the foreseeable future and is thus dependent on the reliability and quality of
parts supplied by these firms. The Company's agreements with its suppliers are
terminable at will or by notice. The Company believes that other suppliers would
be available in the event of termination of these arrangements. No assurance can
be given, however, that the Company will not suffer a material disruption in the
supply of its products.
ACCOUNTING STANDARDS
Accounting standards promulgated by the Financial Accounting Standards Board
change periodically. Changes in such standards may have an impact on the
Company's future financial position.
ADDITIONAL RISK FACTORS
Additional factors that might affect the Company's performance may be listed
from time to time in the reports filed by the Company with the Securities and
Exchange Commission.
18
17
CORPORATE DATA
CHAIRMAN EMERITUS
CHARLES R. ADAMS
OFFICERS
THOMAS E. JONES
Chief Executive Officer
and President
EARL L. YAGER
Executive Vice President,
Chief Financial Officer and Secretary
OSCAR J. SANCHEZ
Vice President, Business Development
ALFONSO DEL TORO
Vice President, Manufacturing
KEVIN MCCULLOH
Vice President, Engineering
DIRECTORS
THOMAS E. JONES
Chief Executive Officer & President
Chad Therapeutics, Inc.
EARL L. YAGER
Executive Vice President
Chad Therapeutics, Inc.
DAVID L. CUTTER
Retired Chairman Of The Board
Cutter Laboratories, Inc.
NORMAN COOPER
Retired Chairman
Kallir, Philips, Ross, Inc.
JOHN C. BOYD
Retired
PHILIP T. WOLFSTEIN
President
Wolfstein International, Inc.
CORPORATE DATA
CORPORATE HEADQUARTERS
21622 Plummer Street
Chatsworth, CA 91311
(818) 882-0883
LEGAL COUNSEL
Graham & James LLP
AUDITORS
KPMG LLP
Los Angeles, California
TRANSFER AGENT AND REGISTRAR
American Stock Transfer Company
40 Wall Street
New York, NY 10005
COMMON STOCK PRICE RANGE
Beginning August 3, 1993, the Company's common shares were traded on the
American Stock Exchange Emerging Company Marketplace and on June 6, 1994, the
Company's shares moved to the primary list of the American Stock Exchange with
the symbol CTU. The following table sets forth, for the periods indicated, the
high and low closing prices as furnished by the American Stock Exchange. Prices
have been adjusted to reflect a 2 for 1 split distributed October 15, 1993, and
a 3 for 2 split distributed on October 16, 1995.
QUARTER ENDED HIGH LOW
- ------------------- ---- ---
June 30, 1998 ........... 8-3/16 5-1/2
September 30, 1998 ...... 6-1/8 2-3/8
December 31, 1998 ....... 3-7/8 1-7/16
March 31, 1999 .......... 2-1/4 1
June 30, 1999 ........... 2-3/4 1-1/2
September 30, 1999 ...... 1-3/8 3/4
December 31, 1999 ....... 1 1/2
March 31, 2000 .......... 2-3/8 3/4
As of June 12, 2000, there were approximately 288 shareholders of record and
approximately 2,800 beneficial owners of the Company's common stock. No cash
dividends have been paid on the common stock.
SEC FORM 10-K
A copy of the Company's annual report to the Securities and Exchange Commission
on Form 10-K is available without charge upon written request to:
Executive Vice President
Chad Therapeutics, Inc.
21622 Plummer Street
Chatsworth, CA 91311
19